Esbriet’s Promise and Potential as a PF Therapy

Marta Ribeiro avatar

by Marta Ribeiro |

Share this article:

Share article via email

pf_esbriet promise

Esbriet (pirfenidone, Genentech) is an anti-fibrotic drug developed as a therapy for pulmonary fibrosis (PF), and was the first drug to receive approval for PF treatment in the United States. New data on Esbriet was recently presented by Dr. Steven Nathan, Medical Director, Advanced Lung Disease and Transplant Program at Inova Fairfax Hospital, at the American College of Chest Physicians Annual Meeting (CHEST 2015), held Oct. 24–28 in Montreal, Canada.


Read more:

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums